Vicore Pharma AB is a pharmaceutical company based in Göteborg that specializes in the development of Angiotensin II Type 2 Receptor Agonists (ATRAGs). The company is focused on creating innovative treatments for conditions such as Idiopathic Pulmonary Fibrosis (IPF). Vicore Pharma is actively conducting clinical trials, including the phase 2a AIR trial, to evaluate the efficacy and safety of its drug candidates.
In addition to its research and development efforts, Vicore Pharma engages in various activities to disseminate knowledge and findings within the pharmaceutical community. The company offers webinars to share insights from its research and provides financial reports and press releases to keep stakeholders informed. Furthermore, Vicore Pharma hosts events related to drug development, emphasizing its commitment to advancing therapeutic potentials and innovative drug mechanisms of action. The organization is supported by a dedicated team with expertise in drug discovery and development, contributing to its mission in the pharmaceutical sector.